Abstract
Objective:
To assess the comparative bioavailability of two formulations (250 mg/5 mL suspension)
of cefuroxime axetil (CAS 64544-07-6), administered with food, in healthy volunteers
of both sexes.
Methods:
The study was conducted using an open, randomized, two-period crossover design with
a 1-week washout interval. Plasma samples were obtained for up to 12 h post dose.
Plasma cefuroxime axetil concentrations were analyzed by liquid chromatography coupled
with tandem mass spectrometry (LC-MS-MS) with negative ion electrospray ionization
using multiple reactions monitoring (MRM). From the cefuroxime axetil plasma concentration
vs. time curves, the following pharmacokinetic parameters were obtained: AUClast and Cmax.
Results:
The limit of quantification was 0.1 μg/mL for plasma cefuroxime axetil analysis. The
geometric mean and 90 % confidence interval CI of test/reference product percent ratios
were: 106.1 %(100.8%–111.8%) for Cmax, 109.4%(104.8 %–114.2%) for AUClast.
Conclusion:
Since the 90% CI for AUClastand Cmax ratios were within the 80–125%interval proposed by the US FDA, it was concluded that
cefuroxime axetil (test formulation, 250 mg/5 mL suspension) was bioequivalent to
a reference formulation under fed conditions, for both the rate and extent of absorption.
Key words
Antibacterial - CAS 64544-07-6 - Cefuroxime axetil, bioavailability, administration
with food, pharmacokinetics - Tandem mass spectrometry, LC/MS/MS
